Scleredema with diffuse pigmentation

Hayashi, Minato; Nishikori, Momoko; Tanioka, Miki; Utani, A.

doi:10.1111/j.1468-3083.2009.03320.x

Cited by 4 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In type 2 scleredema, the prognosis is poor, and careful follow-up and observation are warranted as systemic involvement may occur. It has also been reported to be related to other malignancies such as multiple myelomas in about 1% of cases [ 9 ]. Type 3 also has a poor prognosis similar to type 2 requiring continuous monitoring and follow-up of the diabetic status and metabolic state of the patient [ 4 ].…”

Section: Discussionmentioning

confidence: 99%

“…Treatment of scleredema is supportive in targeting the causative underlying condition as there is no specific treatment for treating the skin condition itself [ 9 ]. Nonetheless, phototherapy is usually the first line of treatment used by many clinicians and if not an effective trial of intravenous immunoglobulin is recommended [ 2 ] We present a case of scleredema that showed different histopathological characteristics than that of typical scleredema mimicking morphea.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Atypical Case of Combined Types I and II Scleredema Mimicking Morphea on Histopathology

Alhunaif¹,

Alsarheed²,

Almutairi³

et al. 2023

Cureus

View full text Add to dashboard Cite

Scleredema is a rare sclerotic skin disorder that typically develops in conjunction with diabetes, monoclonal gammopathy, or infection and commonly involves the neck, back, trunk, and arms. Scleredema can be categorized into three types according to its cause. The local examination of the lesion is characterized by non-pitting induration that follows a symmetrical spread with sparing of the hands and feet. We present a case of a 19-year-old female patient that presented to the outpatient clinic complaining of facial skin lesions that have been progressive for four years. The skin lesions were found to involve the neck, back, trunk and both arms sparing the hands and there was no systemic involvement of the disease. The patient is non-diabetic but reported frequent attacks of tonsillitis over the past months. Initially, punch biopsy showed no signs of scleredema; however, repeated biopsy at follow-up confirmed the presence of mucin deposits which are suggestive features of scleredema. Due to the similarities with various other diseases, the diagnosis requires clinical and histopathological exclusion which makes the diagnosis quite challenging. It almost always starts in the neck but can present initially in rare cases from the face spreading symmetrically. Close follow-up and continuous monitoring are necessary for systemic organ involvement.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Atypical Case of Combined Types I and II Scleredema Mimicking Morphea on Histopathology

Alhunaif¹,

Alsarheed²,

Almutairi³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…If monoclonal gammopathy of unspecified significance is detected, the risk of multiple myeloma or another related malignancy is about 1% per year. Therefore, careful follow‐up of patients is required . The treatment of underlying diseases is crucial; however, this may not be satisfactory in some type 2 scleredema cases.…”

Section: Scleredemamentioning

confidence: 99%

European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis

Knobler

Moinzadeh

Hunzelmann

et al. 2017

J Eur Acad Dermatol Venereol

119

View full text Add to dashboard Cite

The term 'sclerosing diseases of the skin' comprises specific dermatological entities which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, current strategies in the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 2 of this guideline provides clinicians with an overview of the diagnosis and treatment of scleromyxedema, scleredema (of Buschke) and nephrogenic systemic sclerosis (nephrogenic fibrosing dermopathy).

show abstract

Degenerative and metabolic diseases

Brinster¹,

Calonje²

2012

McKee's Pathology of the Skin

View full text Add to dashboard Cite

Scleredema with diffuse pigmentation

Cited by 4 publications

References 5 publications

Atypical Case of Combined Types I and II Scleredema Mimicking Morphea on Histopathology

Atypical Case of Combined Types I and II Scleredema Mimicking Morphea on Histopathology

European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis

Degenerative and metabolic diseases

Contact Info

Product

Resources

About